Translational research of combined anticancer therapies targeting the MAPK pathway

Keyphrases

• Mitogen-activated Protein Kinase 100%
• Translational Research 100%
• Combination Chemotherapy 100%
• BRAF Protein 100%
• Cancer Cells 66%
• KRAS Protein 66%
• MEK Inhibitor (MEKi) 66%
• BRAF Inhibitor (BRAFi) 66%
• Concomitant Treatment 33%
• Anticancer Therapy 33%
• Europe 33%
• Colon Cancer 33%
• Targeted Therapy 33%
• Specificity Protein 1 33%
• Melanoma 33%
• Phase I Study 33%
• Anticancer Treatment 33%
• Cetuximab 33%
• Poor Prognosis 33%
• Drug Combination 33%
• Multiple Drugs 33%
• 3-phase 33%
• Targeted Drugs 33%
• EGFR Inhibitors 33%
• Anticancer Effect 33%
• Overcoming Resistance 33%
• Survival Signaling 33%
• Encorafenib 33%
• Binimetinib 33%
• Protein-resistant 33%
• Intermittent Preventive Treatment 33%
• DNA mutation 33%
• Patient with Tumor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Mitogen Activated Protein Kinase Kinase Inhibitor 66%
• B Raf Kinase 66%
• Colon Carcinoma 33%
• Melanoma 33%
• Encorafenib 33%
• Binimetinib 33%
• Neoplasm 33%
• Epidermal Growth Factor Receptor 33%
• Cetuximab 33%
• Combination Drug 33%

Biochemistry, Genetics and Molecular Biology

• Anticancer 100%
• Mitogen-Activated Protein Kinase 100%
• KRAS 50%
• Cancer Cell 50%
• MEK Inhibitor 50%
• Colon 25%
• DNA Mutation 25%
• Epidermal Growth Factor Receptor 25%
• Cetuximab 25%